The SCIEX clinical diagnostic portfolio is For In Vitro Diagnostic Use. Rx Only. Product(s) not available in all countries. For information on availability, please contact your local sales representative or refer to https://sciex.com/diagnostics. All other products are For Research Use Only. Not for use in Diagnostic Procedures.
Trademarks and/or registered trademarks mentioned herein are the property of AB Sciex Pte. Ltd. or their respective owners in the United States and/or certain other countries.
© 2020 DH Tech. Dev. Pte. Ltd.
Leading Diagnostics Companies Combine to Address Diagnostic and Wellness Testing in China
Framingham, MA and Shanghai, CN — SCIEX Dignostics, the in vitro diagnostics (IVD) division of SCIEX, a global leader in mass spectrometry in the life sciences industry, announced today that it has formed a joint venture (JV) with Zhejiang Dian Diagnostics (Dian), a leader in the research, development and supply of medical diagnostic products and services in China. The parties plan to jointly establish a joint venture in Hangzhou, China to develop, register, manufacture, and commercialize Class I, II and III in vitro diagnostic reagents for the SCIEX Triple Quad™ 4500MD LC-MS/MS system, a solution that was approved by the China Food and Drug Administration (CFDA) earlier this year.
Mass spectrometry is known to achieve the high sensitivity, specificity and throughput needed in clinical testing areas such as therapeutic drug measurement, vitamin and steroid hormones, and measurements of inherited metabolic diseases, but the lack of readily available IVD assays has made this technology inaccessible to the majority of hospital labs in China where lab-developed tests (LDT) are limited. By combining SCIEX LC-MS/MS and assay development expertise, with Dian’s laboratory network, cold chain logistics, and China-IVD manufacturing expertise, it is expected that the partnership will accelerate China’s clinical laboratory program and make diagnostic and wellness testing more widespread in the region.
As one of the leading diagnostic companies in China, Dian's diagnostic network stretches to more than 30 laboratories, covering almost all of mainland China, processing more than 100,000 clinical samples per day. To advance clinical diagnostics in China, Dian has also established "precision treatment centers" with high-end "Tier 3" medical institutions, and has a developed a comprehensive service for secondary-level "Tier 2" hospitals and beyond.
"Modern-day China contends with many lifestyle factors that can lead to illness. Our aim is to provide wellness testing resources that can help hospitals identify potential health risks before they become chronic," said Inese Lowenstein, President of SCIEX. "Dian has established many product channels with its wide coverage of high-end medical resources, and this venture will further enrich their existing in vitro diagnostic product lines to enable hospital labs to expand their testing capabilities, and perform tests that they previously were not able to."
"It is an important decision and major breakthrough for Dian to collaborate with SCIEX to promote the industrialization and localization of clinical mass spectrometry," said Hai bin Chen, Chairman Zhenjang Dian Diagnostics. "This joint venture is the first of its kind in China, and by also working closely with CFDA and Health and Family Planning Commission, we believe it will have a profound influence on the future of wellness and diagnostic testing in China."
A ceremony celebrating the venture will take place at Zhejiang Dian Diagnostics headquarters in Hangzhou, China, on November 11, 2017 attended by SCIEX Senior Leadership Executives.
SCIEX helps to improve the world we live in by enabling scientists and laboratory analysts to find answers to the complex analytical challenges they face. The company's global leadership and world-class service and support in the capillary electrophoresis and liquid chromatography-mass spectrometry industry have made it a trusted partner to thousands of the scientists and lab analysts worldwide who are focused on basic research, drug discovery and development, food and environmental testing, forensics and clinical research.
With over 40 years of proven innovation, SCIEX excels by listening to and understanding the ever-evolving needs of its customers to develop reliable, sensitive and intuitive solutions that continue to redefine what is achievable in routine and complex analysis. For more information, please visit sciex.com.
For Research Use Only. Not for use in diagnostic procedures. IVD-MKT-12-6818-A
AB Sciex is operating as SCIEX.
©2017 AB Sciex. The trademarks mentioned herein are the property of the AB Sciex Pte. Ltd. or their respective owners. AB Sciex™ is being used under license.
Global Marketing Director
+44 1925 236056
Sniper Public Relations on Behalf of SCIEX
A new password has been sent to your email.
You have added a user.
Unfortunately the serial number you provided shows as inactive in our database. Would you like to submit the case anyway?
This serial number could not be found. Would you like to submit the case anyway?
Your password has been updated.
Your account is now created.
A verification link has been sent to your email.
A new password has been sent to your email.
Your insturment has been removed.
Your privacy settings are now updated.
Unfortunately the serial number you provided shows as inactive in our database. Please open a support case here if you require more assistance.
Software has already been registered to another instrument. Please check your AID and try again.
If you want to change the License Key to another instrument, please submit a new case.
Software has already been registered to the instrument selected.
Please check your instrument's software by going to the Instruments page and selecting the instrument in your "My Instruments" section. Here you will see a Software tab where you can view your instrument's software information.
You can also go to the Registered Software page to view software associated with your instrument(s).
If you are not finding what you are looking for, please submit a new case.